+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
E

Actively Recruiting

Researchers are evaluating how lower doses of oral semaglutide can help reduce body weight in adults with excess body weight, including those with overweight or obesity. The study aims to identify the best lower dose of oral semaglutide for treating weight management. This is a phase 3 clinical trial sponsored by Novo Nordisk AS. Participants will be randomly assigned to receive one of two oral doses of semaglutide or a placebo, all combined with a reduced-calorie diet and increased physical activity. The treatment lasts for 60 weeks, during which participants take the study medication daily. The study compares the effects of these doses on body weight and related health measures. Throughout the 60-week study, participants will be monitored for changes in body weight, waist circumference, blood pressure, blood glucose, cholesterol levels, and inflammation markers. Researchers will assess weight loss success at several thresholds 5%, 10%, 15% and track any adverse events up to week 67. Regular visits will include physical assessments and laboratory tests to evaluate safety and effectiveness over the study period.

Age: 18Years +All GendersPhase 3
62 locations